IDXX · Healthcare

IDEXX LABORATORIES INC /DE

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Market Demand TrendsImportance 27 · Surprise 40
  IDEXX reported second-quarter demand growth across its end markets, with Companion Animal Group revenue up 9% organically, Water revenue up 13% organically, and Livestock, Poultry and Dairy revenue up 9% organically.…
• Geographic Market CommentaryImportance 23 · Surprise 24
  IDEXX’s installed base growth for core diagnostic instruments is moderating in the United States. International markets remain at an earlier stage of adoption, providing a longer-term expansion opportunity for…

News · 2026-08-06

• Product Launch and TransitionImportance 31 · Surprise 42
  The inVue Dx cytology analyzer was identified as a key contributor to Companion Animal Diagnostics growth. The product rollout is increasing IDEXX’s diagnostic offering and supporting adoption among veterinary…
• Market Demand TrendsImportance 27 · Surprise 40
  IDEXX reported second-quarter demand growth across its end markets, with Companion Animal Group revenue up 9% organically, Water revenue up 13% organically, and Livestock, Poultry and Dairy revenue up 9% organically.…

10-Q · 2026-08-04

• Middle East conflict impactImportance 10 · Surprise 6
  IDEXX states that hostilities in the Middle East and other global conflicts could disrupt global energy markets, fuel prices, transportation networks, and supply chains. The company identifies the Asia Pacific and…

Earnings call · 2026-08-04

• Free Cash Flow and LiquidityImportance 62 · Surprise 42
  Second-quarter free cash flow was $323 million, bringing first-half 2026 free cash flow to $557 million. Trailing-12-month net-income-to-free-cash-flow conversion was 110%, and full-year conversion guidance was raised…
• Guidance and OutlookImportance 61 · Surprise 76
  IDEXX raised its 2026 revenue outlook to $4.700 billion-$4.745 billion, reflecting a $20 million operational improvement partially offset by the $15 million FX headwind. Full-year organic revenue growth is now expected…
• Operating Expense TrendsImportance 56 · Surprise 58
  Second-quarter operating expenses increased 10% year over year on a reported basis and 9% on a comparable basis. Management expects operating-expense growth to continue through the remainder of 2026 as IDEXX invests in…
• Revenue Performance and MixImportance 48 · Surprise 40
  Second-quarter revenue increased approximately 10% as reported and 9% organically, with nearly 9% organic growth in CAG, 13% growth in Water, and 9% growth in Livestock, Poultry and Dairy. CAG Diagnostics recurring…
• Operating Margin DriversImportance 46 · Surprise 40
  Comparable operating margin increased 110 basis points in the second quarter, while reported operating margin reached 35%. Comparable operating profit increased 12%, benefiting from recurring revenue growth, favorable…
• Product Launch and TransitionImportance 44 · Surprise 42
  IDEXX placed 2,700 inVue Dx instruments in the first half and 1,602 in Q2, with full-year placements expected to reach 5,500. The controlled rollout of inVue Dx FNA is expanding into Q3, with broad availability planned…
• Capital Expenditure OutlookImportance 44 · Surprise 24
  IDEXX maintained its 2026 capital spending outlook at approximately $180 million. The spending plan is incorporated into the company’s updated free-cash-flow conversion expectation of 90%-100% of net income. Management…
• Diagnostic Utilization ExpansionImportance 42 · Surprise 40
  IDEXX VetLab consumable revenue increased 14% organically, driven by net new premium-instrument customers and expanded testing utilization. The company said most U.S. wellness visits still do not include bloodwork,…
• FX / Currency HeadwindsImportance 32 · Surprise 24
  Updated 2026 guidance includes a $15 million revenue headwind from foreign-currency changes versus prior estimates. Foreign exchange is expected to provide an approximately 60-basis-point benefit to reported full-year…
• Competition and Market ShareImportance 31 · Surprise 32
  IDEXX reported global CAG Diagnostics customer retention in the high 90s and an installed base that grew 11% year over year. More than 20% of Cancer Dx orders globally came from practices using a competitive…
• Geographic Market CommentaryImportance 31 · Surprise 42
  Management plans to expand field presence across four international countries during the remainder of 2026, alongside targeted additions in the United States. The strategy is intended to develop veterinary diagnostics…
• Gross Margin DriversImportance 30 · Surprise 40
  Second-quarter gross margin was 64%, an approximately 120-basis-point comparable improvement from the prior year. Gross profit increased 12% as reported and 11% on a comparable basis, supported by strong recurring…
• Market Demand TrendsImportance 25 · Surprise 32
  U.S. same-store clinical visits declined 1.3% in Q2, with wellness visits down more than 3% while non-wellness visits showed modest growth. Pets aged five and older generated positive growth across both wellness and…
• Macroeconomic Factors ImpactImportance 25 · Surprise 32
  Management said broad inflationary pressure and elevated gas and housing costs are weighing on discretionary veterinary demand in the United States. Wellness visits were down below 3% year over year, while non-wellness…
• Capital Return ProgramImportance 23 · Surprise 24
  IDEXX continues to evaluate share buybacks against potential mergers, acquisitions, and in-licensing opportunities. Management said excess cash has primarily been returned through share repurchases because of its…
• Acquisition / Partnership / DivestitureImportance 21 · Surprise 24
  Management said organic growth remains IDEXX's core investment priority, while business development is being assessed opportunistically. The company is focused on potential assets in diagnostics and software, noting…

8-K · 2026-08-04

• Capital Expenditures and Cash FlowImportance 85 · Surprise 64
  Six-month cash flow from operations increased 45% to $613.4 million from $423.7 million. Six-month free cash flow increased 55% to $556.8 million from $359.6 million after $56.6 million of property and equipment…
• Guidance / OutlookImportance 85 · Surprise 76
  IDEXX narrowed its 2026 revenue guidance to $4,700 million-$4,745 million, raising the midpoint by $5 million and forecasting reported growth of 9.1%-10.3% and organic growth of 8.5%-9.7%. CAG Diagnostics recurring…
• Liquidity and Debt PositionImportance 81 · Surprise 64
  Cash and cash equivalents increased to $196.9 million at June 30, 2026 from $180.1 million at December 31, 2025. The line of credit increased to $519.0 million from $398.0 million, while current long-term debt…
• Guidance and OutlookImportance 80 · Surprise 68
  IDEXX narrowed 2026 revenue guidance to $4,700 million-$4,745 million, with reported growth of 9.1%-10.3% and organic growth of 8.5%-9.7%. The midpoint increased by $5 million, despite a projected $15 million revenue…
• Capital Return ProgramImportance 63 · Surprise 50
  IDEXX repurchased $692.9 million of common stock in the open market during the first six months of 2026, compared with $736.7 million in the prior-year period. Including employee shares surrendered for tax withholding,…
• Income Tax Rate ChangesImportance 57 · Surprise 22
  Second-quarter income tax provision increased to $78.8 million from $68.4 million as pretax income increased to $417.2 million from $362.4 million. The quarter included a $0.14-per-share tax benefit from share-based…
• Geographic Revenue ShiftImportance 54 · Surprise 40
  Total U.S. revenue increased 7.7% to $773.0 million in the second quarter, while international revenue increased 13.3% to $443.6 million. International revenue represented approximately 36.5% of quarterly revenue, up…
• Gross Margin DriversImportance 54 · Surprise 40
  Second-quarter gross profit increased 12% reported and 11% on a comparable basis to $779.1 million. Gross margin expanded 140 basis points reported to 64.0% and 120 basis points on a comparable basis. Management…
• Operating Income and MarginsImportance 54 · Surprise 40
  Second-quarter operating income increased 14% to $425.6 million from $373.0 million. Operating margin increased to 35.0% from 33.6%, a 140-basis-point reported expansion and 110-basis-point comparable expansion. CAG…
• Market Demand TrendsImportance 54 · Surprise 40
  CAG Diagnostics recurring revenue grew 11% reported and 10% organically, with 12% organic growth internationally and 10% in the U.S. Growth was volume-driven and supported by customer expansion, IDEXX innovations, and…
• Geographic Market CommentaryImportance 54 · Surprise 40
  International markets grew faster than the U.S. across the company, with total international revenue up 13.3% reported and 11.2% organically versus 7.7% U.S. growth. CAG revenue increased 13.4% reported and 11.5%…
• Product Launch and TransitionImportance 49 · Surprise 66
  IDEXX said innovation across its Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supported deeper customer adoption and higher diagnostic utilization. The IDEXX inVue Dx installed base surpassed 9,000 instruments…
• Litigation and Legal RiskImportance 49 · Surprise 60
  IDEXX concluded litigation over alleged underpayment of royalties from 2004 through 2017 under an expired patent license agreement. After the trial court ruled for the plaintiff in 2020 and appeals followed, IDEXX paid…
• Water And LPD DemandImportance 48 · Surprise 40
  Water revenue grew 15% reported and 13% organically in the quarter, reflecting solid organic growth in the U.S. and Europe. LPD revenue increased 11% reported and 9% organically. LPD growth was led by the Americas. The…
• Revenue Performance and MixImportance 47 · Surprise 22
  Second-quarter revenue was $1,216.6 million, up 9.7% reported and 9.0% organically from $1,109.5 million in the prior-year quarter. CAG revenue increased 9.4% to $1,118.2 million, Water revenue increased 14.8% to $58.6…
• Operating Expense TrendsImportance 46 · Surprise 22
  Second-quarter operating expenses increased 10% reported and 9% on a comparable basis to $353.5 million from $321.7 million. Sales and marketing expense rose to $171.3 million from $161.1 million, while general and…
• Net Income and EPS PerformanceImportance 42 · Surprise 22
  Second-quarter diluted EPS increased 18% to $4.27 from $3.63, or 15% on a comparable basis to $4.07. Net income attributable to stockholders increased to $338.4 million from $294.0 million. EPS included a…
• FX / Currency HeadwindsImportance 26 · Surprise 24
  IDEXX reduced projected 2026 revenue by $15 million because of updated foreign-exchange estimates and expects currency to affect EPS by approximately $0.22. The company estimates foreign currency will reduce 2026…

News · 2026-08-04

• Guidance / OutlookImportance 57 · Surprise 60
  Third-party reports said IDEXX raised its full-year 2026 outlook after second-quarter results. The company projected 2026 revenue of $4.70 billion to $4.75 billion and adjusted EPS of $14.69 to $14.94. Reports…
• Revenue Performance and MixImportance 35 · Surprise 22
  IDEXX Laboratories reported second-quarter 2026 revenue of $1,217 million, up 10% year over year on a reported basis and 9% organically. Companion Animal Group revenue increased 9% on both reported and organic bases,…